НовостиBenzingaCerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported Benzinga 2026.11.16 12:32 (GMT+0) Открыть на Benzinga Другие новости